{"organizations": [], "uuid": "89348c6e142df4b8a9c799a69b2c17022fb6d61d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/UKBankingFinancial", "section_title": "Reuters: Financial Services and Real Estate", "url": "https://www.reuters.com/article/healthscope-ltd-ma/australias-healthscope-denies-access-to-brookfield-bgh-capital-idUSL3N1SS5GA", "country": "US", "domain_rank": 408, "title": "Australia's Healthscope denies access to Brookfield, BGH Capital", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-22T01:54:00.000+03:00", "replies_count": 0, "uuid": "89348c6e142df4b8a9c799a69b2c17022fb6d61d"}, "author": "", "url": "https://www.reuters.com/article/healthscope-ltd-ma/australias-healthscope-denies-access-to-brookfield-bgh-capital-idUSL3N1SS5GA", "ord_in_thread": 0, "title": "Australia's Healthscope denies access to Brookfield, BGH Capital", "locations": [], "entities": {"persons": [{"name": "ambar warrick", "sentiment": "none"}], "locations": [{"name": "australia", "sentiment": "none"}, {"name": "brookfield", "sentiment": "none"}, {"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "healthscope", "sentiment": "negative"}, {"name": "bgh capital", "sentiment": "negative"}, {"name": "reuters", "sentiment": "none"}, {"name": "bgh capital reuters", "sentiment": "none"}, {"name": "brookfield asset management", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 22 (Reuters) - Australian hospital group Healthscope said on Tuesday it would not provide due diligence access for takeover offers worth more than $3 billion each from Brookfield Asset Management and BGH Capital, stating both offers undervalue the company.\nIn a separate announcement, the company said it had received a number of suitors for its Asian Pathology business and had initiated a sale process.\nThe company also said it expected core earnings from hospital operations to be in the range of A$340 million to A$345 million ($257.89 million-$261.68 million) for fiscal 2018, compared to core earnings of A$359.4 million in 2017. ($1 = 1.3184 Australian dollars) (Reporting by Ambar Warrick in Bengaluru)\n ", "external_links": [], "published": "2018-05-22T01:54:00.000+03:00", "crawled": "2018-05-22T02:51:51.004+03:00", "highlightTitle": ""}